Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2868414 | 0.88 | ADORA3 (0.51) | ADORA3ADORA1ALDH1A1HPGDLMNA | |
| SCHEMBL2864647 | 0.81 | PDE2A (0.44) | ADORA3PARP1ALDH1A1HPGDLMNA | |
| SCHEMBL2870092 | 0.78 | KDM4E (0.53) | ADORA3PARP1ALDH1A1NPC1KDM4E | |
| SCHEMBL2864783 | 0.77 | KDM4E (0.53) | ADORA3ALDH1A1HPGDPDE2ANPC1 | |
| SCHEMBL2865098 | 0.76 | KDM4E (0.49) | ALDH1A1HPGDLMNANPC1KDM4E | |
| SCHEMBL2866719 | 0.71 | PDE2A (0.43) | ALDH1A1HPGDLMNAPDE2AKDM4E | |
| SCHEMBL2870546 | 0.69 | PDE2A (0.47) | ADORA3ADORA1ALDH1A1HPGDPDE2A | |
| SCHEMBL2861961 | 0.69 | CTSV (0.42) | PARP1ALDH1A1HPGDLMNAPDE2A | |
| SCHEMBL2857864 | 0.68 | ADORA3 (0.83) | ADORA3ADORA1LMNATP53 | |
| SCHEMBL2862251 | 0.68 | PDE2A (0.42) | ADORA3ADORA1PDE2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842701-B2 | Pyrazoloquinolone derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-7842701-B2 | Pyrazoloquinolone derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-7842701-B2 | Pyrazoloquinolone derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-12-06 | — | — | US | disclosed |
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-12-06 | — | — | US | disclosed |
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-12-06 | — | — | US | disclosed |
| EP-1719771-A1 | PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | MAP3K20, MAP4K5, MAP4K3 | ADORA3 1829/4885ADORA1 2477/4885PARP1 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.